Cargando…
Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway
Although targeted therapy and immunotherapy greatly improve the outcome of melanoma, drug resistance and low response rates still maintain the unsubstitutability of traditional chemotherapy. Cisplatin (CDDP) is widely used in different types of tumours with high response rates, but it generally has...
Autores principales: | Sun, Xuerong, Shi, Benyan, Zheng, Huiling, Min, Ling, Yang, Jie, Li, Xiaoyi, Liao, Xiaoxin, Huang, Weixing, Zhang, Mingmeng, Xu, Shun, Zhu, Zhe, Cui, Hongjing, Liu, Xinguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833767/ https://www.ncbi.nlm.nih.gov/pubmed/29449532 http://dx.doi.org/10.1038/s41419-018-0303-9 |
Ejemplares similares
-
Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023) -
IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma
por: Homann, Lorenzo, et al.
Publicado: (2022) -
RSK1 activation promotes invasion in nodular melanoma
por: Salhi, Amel, et al.
Publicado: (2015) -
Cell senescence, the senescence-associated secretory phenotype, and cancers
por: Langhi Prata, Larissa G. P., et al.
Publicado: (2023) -
Mitofusins modulate the increase in mitochondrial length, bioenergetics and secretory phenotype in therapy-induced senescent melanoma cells
por: Martínez, Jennyfer, et al.
Publicado: (2019)